Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$15.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company announces CHMP recommends Empagliflozin for approval to reduce blood Sugar Levels in Adults with Type 2 Diabetes in Europe


Friday, 21 Mar 2014 08:25am EDT 

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company:Positive opinion from Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency, recommending approval of empagliflozin.Says an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D).Positive opinion is based on results from one of clinical registration programs in its class, comprised of more than 10 multinational clinical trials and more than 13,000 adults with T2D.Following CHMP positive opinion, European Commission generally follows the recommendation and usually issues its final decision on marketing authorization within two months. 

Company Quote

84.51
-0.03 -0.04%
31 Jul 2015